Endocrine therapy resistance is a major challenge in the treatment of ER+ breast cancer, and our study provides new insights into how HSD3B1 upregulation following long-term estrogen deprivation (LTED) and tamoxifen treatment supports cell survival and sustains ER signaling, ultimately contributing to therapy resistance. The gene discussed is ESR1; the disease is breast carcinoma.